BCM
MRNS

Bluefin Capital Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Bluefin Capital Management’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-4,415
Closed -$27K – 760
2019
Q3 		$27K Buy
+4,415
New +$35.7K ﹤0.01% 415

Other funds holding MRNS

LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Bluefin Capital Management's MRNS Position: Q4 2019 in Review

Bluefin Capital Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q4 2019, closing a stake of 4,415 shares — an estimated $27K sold.

Bluefin Capital Management first reported a position in MRNS in Q3 2019 and held it in 1 quarter. The position peaked at $27K in Q3 2019. 79 funds tracked by Wall St. Rank hold MRNS as of Q4 2019.

  • Bluefin Capital Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q4 2019 after selling out during the quarter.
  • Bluefin Capital Management sold 4,415 Marinus Pharmaceuticals, Inc shares in Q4 2019, an estimated $27K.
  • Bluefin Capital Management first reported a position in Marinus Pharmaceuticals, Inc in Q3 2019 and held it in 1 quarter.
  • Bluefin Capital Management's Marinus Pharmaceuticals, Inc position peaked at $27K in Q3 2019.
  • 79 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2019.

Based on Bluefin Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.